MARKET

NURPF

NURPF

Neuren Pharma
OTCPK
13.46
NaN%
Closed 09:30 07/02 EDT
OPEN
--
PREV CLOSE
13.46
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
15.15
52 WEEK LOW
7.83
MARKET CAP
1.71B
P/E (TTM)
86.67
1D
5D
1M
3M
1Y
5Y
1D
Neuren Pharmaceuticals Limited (NURPF) Gets a Buy from Macquarie
TipRanks · 5d ago
Canaccord Genuity Keeps Their Buy Rating on Neuren Pharmaceuticals Limited (NURPF)
TipRanks · 5d ago
Bell Potter Sticks to Their Buy Rating for Neuren Pharmaceuticals Limited (NURPF)
TipRanks · 6d ago
Neuren Set for Major EU Milestone as EMA Backs DAYBU for Rett Syndrome
TipRanks · 6d ago
Neuren Pharmaceuticals Seeks ASX Quotation for 450,000 New Shares
TipRanks · 06/18 07:07
Neuren Issues 360,000 Unquoted Shares Under Employee Incentive Scheme
TipRanks · 06/01 08:00
Neuren Investors Back Board and CEO Options but Reject Constitution Changes
TipRanks · 05/27 06:38
Neuren Leverages DAYBUE Windfall to Drive NNZ-2591 Phase 3 Push in Rare Neurological Disorders
TipRanks · 05/27 03:32
More
About NURPF
Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product, NNZ-2591, is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.

Webull offers Neuren Pharmaceuticals Ltd stock information, including OTCPK: NURPF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NURPF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NURPF stock methods without spending real money on the virtual paper trading platform.